Tirzepatide represents the next generation of weight loss medications. Sold under the brand names Zepbound® (approved for weight management) and Mounjaro® (approved for type 2 diabetes), tirzepatide is a first-in-class dual-action medication that works differently from single-target GLP-1 drugs like semaglutide. By activating two distinct metabolic pathways simultaneously, tirzepatide has produced some of the most significant weight loss results ever seen in clinical trials.
What makes tirzepatide unique is its dual-receptor approach. While semaglutide and other GLP-1 medications target a single pathway, tirzepatide activates two:
The combination of these two pathways means tirzepatide addresses appetite and metabolism from multiple angles. For many patients, this translates to greater appetite suppression and more significant weight loss than single-target GLP-1 medications alone.
The SURMOUNT clinical trial program has produced compelling data across thousands of patients. In the landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking tirzepatide at the 15 mg dose achieved an average weight loss of 22.5% over 72 weeks — with over one-third of participants losing 25% or more of their body weight. The three-year extension of this trial showed sustained results, with an average weight reduction of 22.9% at the 15 mg dose.
More recently, the SURMOUNT-5 trial provided the first head-to-head comparison against semaglutide, demonstrating tirzepatide's superiority in weight reduction. These results have positioned tirzepatide as one of the most effective pharmaceutical interventions available for obesity management.
Greater weight loss potential comes with greater responsibility. When patients lose 20% or more of their body weight, the risk of losing significant muscle mass alongside fat increases substantially. Without structured nutritional counseling focused on adequate protein intake and macro balance, patients on tirzepatide face elevated risk of muscle loss, bone density reduction, and nutritional deficiencies — potentially more so than with milder weight loss interventions, precisely because the weight comes off faster and in greater quantities.
This is why our GLP-1 program exists. Your team monitors your body composition at every visit — tracking not just total weight loss but the ratio of fat to lean mass. Your nutrition plan is calibrated to protect muscle while maximizing fat loss. And your medication dosage is adjusted based on real clinical data from your body, not a predetermined schedule. The Medi-Weightloss program wraps all of this into a structured three-phase approach that carries you from active weight loss through to long-term maintenance.
Tirzepatide's side effect profile is similar to other GLP-1 medications. The most common adverse effects reported in clinical trials were gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and constipation. These were predominantly mild to moderate in severity and tended to decrease as participants adjusted to the medication over several weeks. In the SURMOUNT-5 trial, discontinuation rates due to side effects were low for both tirzepatide and semaglutide.
Under medical supervision, your provider manages side effects proactively — adjusting your dose escalation schedule, modifying your nutrition plan to minimize GI discomfort, and monitoring for any less common complications. This active management is a significant advantage over unsupervised use. For more detail, see our GLP-1 side effects guide.
Branded tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) can be expensive without insurance coverage. However, an increasing number of insurance plans now cover GLP-1 medications for weight management, and compounded alternatives may be available at lower cost. Coverage depends on your specific carrier, plan, and clinical situation.
Our team at Elk Grove Village and Algonquin helps you navigate your insurance coverage during your assessment and identifies the most cost-effective path. Call (847) 262-4300 or (847) 805-3630 with questions.